Open | $31.670 |
Close | $31.590 |
Volume / Avg. | 367.875K / 373.795K |
Day Range | 31.370 - 32.450 |
52 Wk Range | 18.611 - 45.170 |
Market Cap | $1.793B |
P/E Ratio | 14.831 |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 47 |
Short Interest | 33.89% |
Days to Cover | 22.98 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Harmony Biosciences (NASDAQ: HRMY) through any online brokerage.
Other companies in Harmony Biosciences’s space includes: Supernus Pharmaceuticals (NASDAQ:SUPN), Verona Pharma (NASDAQ:VRNA), CymaBay Therapeutics (NASDAQ:CBAY), Neumora Therapeutics (NASDAQ:NMRA) and ANI Pharmaceuticals (NASDAQ:ANIP).
The latest price target for Harmony Biosciences (NASDAQ: HRMY) was reported by Mizuho on Tuesday, February 27, 2024. The analyst firm set a price target for 40.00 expecting HRMY to rise to within 12 months (a possible 26.62% upside). 35 analyst firms have reported ratings in the last year.
The stock price for Harmony Biosciences (NASDAQ: HRMY) is $31.59 last updated March 18, 2024 at 4:00 PM EDT.
There are no upcoming dividends for Harmony Biosciences.
Harmony Biosciences’s Q1 earnings are confirmed for Tuesday, April 30, 2024.
There is no upcoming split for Harmony Biosciences.
Harmony Biosciences is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.